Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.



In thousands of US dollars ($)	Year Ended December 31, 2019
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales - Point-in-time	$	272	$	272	$	—
License Fee – Over time	273		—		273
Total Drug Products	545		272		273
Concentrate Products
Product Sales – Point-in-time	58,778		52,540		6,238
License Fee – Point-in-time	1,980		1,980		—
Total Concentrate Products	60,758		54,520		6,238
Net Revenue	$	61,303	$	54,792	$	6,511

	Year Ended December 31, 2018
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	273	$	—	$	273
Concentrate Products
Product Sales – Point-in-time	60,995		52,264		8,731
License Fee – Point-in-time	2,121		2,121		—
Total Concentrate Products	63,116		54,385		8,731
Net Revenue	$	63,389	$	54,385	$	9,004

Contract balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.



In thousands of US dollars ($)	December 31, 2019		December 31, 2018
Receivables, which are included in "Trade and other receivables"	$	4,203	$	6,980
Contract liabilities	$	12,076	$	14,329

Summary of potentially dilutive securities

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2019 and 2018 were as follows:



	As of December 31,
	2019	2018
Options to purchase common stock	8,598,149	8,244,605
Unvested restricted stock awards	146,800	146,800
Unvested restricted stock units	1,452,744	1,461,917
Warrants to purchase common stock	2,770,781	2,770,781
	12,968,474	12,624,103